Calidi Biotherapeutics (NASDAQ: CLDI) furnishes updated corporate presentation

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Calidi Biotherapeutics, Inc. filed a current report to note that it has made an updated corporate presentation available on its website. The presentation is included as Exhibit 99.1 and is furnished under Regulation FD, meaning it is provided for informational disclosure and is not deemed filed for liability purposes under the Exchange Act or automatically incorporated into other securities law filings.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

02/09/2026 - 08:08 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 6, 2026

CALIDI BIOTHERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-40789

86-2967193

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

4475 Executive Drive, Suite 200,

San Diego, California

92121

(Address of principal executive offices)

(Zip Code)

(858) 794-9600

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common stock, par value $0.0001 per share		CLDI		NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On February 6, 2026, Calidi Biotherapeutics, Inc. (the “Company”) made available on its website an updated presentation in relation to the Company. Furnished as Exhibit 99.1 hereto and incorporated by reference herein is the presentation.

By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. The information in this Item 7.01 disclosure, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section. In addition, the information in this Item 7.01 disclosure, including Exhibits 99.1, shall not be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit		Exhibit Description
99.1		Presentation
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CALIDI BIOTHERAPEUTICS, INC.
Dated: February 9, 2026
	By:	/s/ Andrew Jackson
	Name:	Andrew Jackson
	Title:	Chief Financial Officer

Exhibit 99.1

Source: View Original Filing on SEC EDGAR

FAQ

What did Calidi Biotherapeutics (CLDI) announce in this 8-K?

Calidi Biotherapeutics announced that it has made an updated corporate presentation available on its website. The same presentation is furnished as Exhibit 99.1 to the report under Regulation FD disclosure rules.

What is included as Exhibit 99.1 in Calidi Biotherapeutics’ 8-K?

Exhibit 99.1 is a presentation related to Calidi Biotherapeutics. The company states it made this updated presentation available on its website and furnished it with the report for fair disclosure purposes.

Is the Calidi Biotherapeutics (CLDI) presentation considered filed with the SEC?

The company states the information in Item 7.01 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act. This limits how the information is treated for certain liability provisions and incorporation into other filings.

Does the Calidi Biotherapeutics 8-K indicate any major transaction or earnings update?

This report focuses on an updated corporate presentation and Regulation FD disclosure. It does not describe major transactions or earnings data, instead emphasizing the availability and legal treatment of the furnished presentation.

Where can investors access the Calidi Biotherapeutics updated presentation?

Calidi Biotherapeutics states that the updated presentation has been made available on its website. The same materials are also furnished as Exhibit 99.1 to the report for consistent public access and fair disclosure.

Who signed the Calidi Biotherapeutics (CLDI) 8-K report?

The report was signed on behalf of Calidi Biotherapeutics by Andrew Jackson, Chief Financial Officer. His signature indicates company authorization of the furnished Regulation FD disclosure and exhibit listing in the document.

Filing Exhibits & Attachments

27 documents